Corvus Pharmaceuticals (CRVS) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.22

Estimate

-$0.20

Surprise

-7.3%

Score today

5.4/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Corvus Pharmaceuticals (CRVS) reported a wider loss than forecast — adjusted EPS of -$0.22 against the -$0.20 estimate (a 7.3% shortfall).

• Corvus Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update — fiscal.ai, 2026-11-05
• Corvus Pharma Q3 2026 Earnings Call Transcript — benzinga, 2026-11-05
• Corvus Says Angel Pharma’s China Atopic Dermatitis Cohort 1 Data Expected In March 2027; Phase 2 Asthma Trial To Start B — benzinga, 2026-11-05

TrendMatrix currently rates CRVS Sell at 5.4/10; no pre/post engine snapshot brackets this report.

0 of the last 4 quarters beat the estimate; this quarter's -7.3% surprise compares with a -7.9% four-quarter average. Next scheduled report: 2027-03-11.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$10.54

Price target

$27.41

Stop

$9.80

Upside to target

+160.1%

Reward-to-risk

12.7:1

Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$886.6M

P/E (fwd)

-9.9

52-week range

$6.39–$26.95

Off 52-week high

60.9%

RSI (14)

59

Volume vs avg

1.22×

Score today

5.4/10